Exclusive Summary

• Targeting a massive anti-infective market, it is listed on the WHO Essential Medicines List, representing an inelastic, high-turnover daily utility drug with stable global demand.
• With originator patents long expired globally, there are zero IP risks; the focus is on high cost-effectiveness and supply chain stability, perfectly suited for public procurement tenders in emerging markets.
• The 0.25g dosage perfectly matches the classic short-course, once-daily regimen, offering high patient compliance and serving as a first-line treatment for chlamydia and atypical pneumonia.
• Leveraging China's mature "API + Formulation" integrated production capacity, it guarantees overseas distributors highly competitive pricing and reliable delivery with no shortage risks.